Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
Pilot programs will start soon as Novo Nordisk uses OpenAI to speed drug discovery and improve operations, while training its global workforce.
- On Tuesday, Danish drugmaker Novo Nordisk announced a partnership with OpenAI to deploy artificial intelligence across drug discovery, manufacturing, and commercial operations.
- Novo is seeking to regain ground in the intensifying obesity-drug market against Indianapolis-based Eli Lilly, which this month won U.S. approval for its Foundayo weight-loss pill.
- Pilot programmes begin immediately across research and development, manufacturing, and commercial operations, with full integration planned by the end of 2026; OpenAI will train the global workforce to boost AI literacy.
- CEO Mike Doustdar said the collaboration aims to "supercharge" employees rather than replace them, seeking to lift productivity and curb future hiring pace following last year's 9,000-job restructuring.
- OpenAI CEO Sam Altman said artificial intelligence can "accelerate scientific discovery and redefine patient care," though experts caution that AI models have yet to master the "holy grail" of drug development.
43 Articles
43 Articles
OpenAI Teams with Novo Nordisk to Speed Prescription Drug Development
Anyone who moved to Hollywood with superstar dreams will sympathize. Now that its career as a movie-maker has stalled, OpenAI is pivoting to pharmaceuticals. Weeks after shuttering Sora, its consumer AI video generator, and amid a broader shift away from “side quests” and toward revenue-generating enterprise markets, OpenAI on Tuesday announced a partnership with Novo Nordisk to help the Wegovy-maker use AI to accelerate drug discovery. It’s a …
Novo Nordisk partners with OpenAI to use AI for speeding up drug development
Danish Drugmaker Novo Nordisk said on Tuesday it is partnering with OpenAI to use artificial intelligence across its business, from drug discovery to manufacturing and commercial operations. The company, which is the maker of weight loss drugs Wegovy and Ozempic, said the partnership would use OpenAI’s technology to analyze complex datasets, identify promising drug candidates and improve efficiency in manufacturing, supply chains, distributio…
Novo Nordisk Partners with OpenAI to Accelerate Drug Development - Indianapolis Today
Novo Nordisk, the maker of weight-loss drugs Wegovy and Ozempic, has announced a partnership with OpenAI to deploy artificial intelligence across its business. The collaboration will use OpenAI's technology to analyze complex datasets, identify promising drug candidates, and improve efficiency in manufacturing, supply chains, distribution, and corporate operations. Novo Nordisk is seeking new ways to regain ground in the intensifying obesity-dru…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
